Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling
Authors
Keywords
EphA2, HCC, AKT, STAT3, JAK1
Journal
Cell Reports
Volume 34, Issue 8, Pages 108765
Publisher
Elsevier BV
Online
2021-02-24
DOI
10.1016/j.celrep.2021.108765
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tissue-specificity in cancer: The rule, not the exception
- (2019) Kevin M. Haigis et al. SCIENCE
- EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer.
- (2019) Giulia Martini et al. MOLECULAR CANCER THERAPEUTICS
- AKT as a Therapeutic Target for Cancer
- (2019) Mengqiu Song et al. CANCER RESEARCH
- FAK and β‐Catenin Cooperate to Induce Hepatocellular Carcinoma
- (2019) Shang Na et al. HEPATOLOGY
- Hepatocellular Carcinoma
- (2019) Augusto Villanueva NEW ENGLAND JOURNAL OF MEDICINE
- Tumor cell–intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2)
- (2019) Nune Markosyan et al. JOURNAL OF CLINICAL INVESTIGATION
- Overriding adaptive resistance to sorafenib via combination therapy with SHP2 blockade in hepatocellular carcinoma
- (2019) Carmen Oi Ning Leung et al. HEPATOLOGY
- Jak-Stat Signaling Induced by Interleukin-6 Family Cytokines in Hepatocellular Carcinoma
- (2019) Lokau et al. Cancers
- Targeting the IL-6/JAK/STAT3 signalling axis in cancer
- (2018) Daniel E. Johnson et al. Nature Reviews Clinical Oncology
- Kinase inhibitors: the road ahead
- (2018) Fleur M. Ferguson et al. NATURE REVIEWS DRUG DISCOVERY
- Deregulation of miR-520d-3p promotes hepatocellular carcinoma development via lncRNA MIAT regulation and EPHA2 signaling activation
- (2018) Yun Xiang et al. BIOMEDICINE & PHARMACOTHERAPY
- Do STAT3 inhibitors have potential in the future for cancer therapy?
- (2017) Andrea L.A. Wong et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
- (2017) Zefang Tang et al. NUCLEIC ACIDS RESEARCH
- Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers
- (2017) W Song et al. ONCOGENE
- EphA2 is an epithelial cell pattern recognition receptor for fungal β-glucans
- (2017) Marc Swidergall et al. Nature Microbiology
- EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer
- (2016) Katherine R. Amato et al. CANCER RESEARCH
- IL-6 trans-signaling is essential for the development of hepatocellular carcinoma in mice
- (2016) Juri Bergmann et al. HEPATOLOGY
- Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant β-catenin
- (2016) Junyan Tao et al. HEPATOLOGY
- Mechanisms of ephrin–Eph signalling in development, physiology and disease
- (2016) Artur Kania et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- AKT-STAT3 Pathway as a Downstream Target of EGFR Signaling to Regulate PD-L1 Expression on NSCLC cells
- (2016) Sherif Abdelhamed et al. Journal of Cancer
- A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib
- (2016) Tobias Sinnberg et al. EBioMedicine
- Advances in targeted therapies for hepatocellular carcinoma in the genomic era
- (2015) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- Ubiquitination switches EphA2 vesicular traffic from a continuous safeguard to a finite signalling mode
- (2015) Ola Sabet et al. Nature Communications
- Focal Gains of VEGFA: Candidate Predictors of Sorafenib Response in Hepatocellular Carcinoma
- (2014) Josep M. Llovet CANCER CELL
- FAK Is required for c-Met/β-catenin-driven hepatocarcinogenesis
- (2014) Na Shang et al. HEPATOLOGY
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC
- (2014) Katherine R. Amato et al. JOURNAL OF CLINICAL INVESTIGATION
- CRISPR-mediated direct mutation of cancer genes in the mouse liver
- (2014) Wen Xue et al. NATURE
- EphA2 promotes infiltrative invasion of glioma stem cells in vivo through cross-talk with Akt and regulates stem cell properties
- (2014) H Miao et al. ONCOGENE
- Human and Mouse VEGFA-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment
- (2014) E. Horwitz et al. Cancer Discovery
- Loss of Androgen Receptor Expression Promotes a Stem-like Cell Phenotype in Prostate Cancer through STAT3 Signaling
- (2013) A. Schroeder et al. CANCER RESEARCH
- Signal Transducer and Activator of Transcription 3 (STAT3) Degradation by Proteasome Controls a Developmental Switch in Neurotrophin Dependence
- (2013) Sachiko Murase JOURNAL OF BIOLOGICAL CHEMISTRY
- Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends
- (2013) Matthias S. Matter et al. JOURNAL OF HEPATOLOGY
- Therapeutic targeting of EPH receptors and their ligands
- (2013) Andrew W. Boyd et al. NATURE REVIEWS DRUG DISCOVERY
- EphA2-Induced Angiogenesis in Ewing Sarcoma Cells Works through bFGF Production and Is Dependent on Caveolin-1
- (2013) Miguel Sáinz-Jaspeado et al. PLoS One
- Multiplex Genome Engineering Using CRISPR/Cas Systems
- (2013) L. Cong et al. SCIENCE
- EphA2 Signaling Following Endocytosis: Role of Tiam1
- (2013) Pomme Boissier et al. TRAFFIC
- The EphA2 Receptor Drives Self-Renewal and Tumorigenicity in Stem-like Tumor-Propagating Cells from Human Glioblastomas
- (2012) Elena Binda et al. CANCER CELL
- Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells
- (2012) Nicole Grabinski et al. Molecular Cancer
- Coactivation of AKT and -Catenin in Mice Rapidly Induces Formation of Lipogenic Liver Tumors
- (2011) J. K. Stauffer et al. CANCER RESEARCH
- Dasatinib: An Anti-Tumour Agent via Src Inhibition
- (2011) Antonio Gnoni et al. CURRENT DRUG TARGETS
- A public genome-scale lentiviral expression library of human ORFs
- (2011) Xiaoping Yang et al. NATURE METHODS
- Hepatocyte IKKβ/NF-κB Inhibits Tumor Promotion and Progression by Preventing Oxidative Stress-Driven STAT3 Activation
- (2010) Guobin He et al. CANCER CELL
- A Unique Metastasis Gene Signature Enables Prediction of Tumor Relapse in Early-Stage Hepatocellular Carcinoma Patients
- (2010) S. Roessler et al. CANCER RESEARCH
- Tyrosine Phosphorylation Profiling Reveals the Signaling Network Characteristics of Basal Breast Cancer Cells
- (2010) F. Hochgrafe et al. CANCER RESEARCH
- NF-κB and STAT3 – key players in liver inflammation and cancer
- (2010) Guobin He et al. CELL RESEARCH
- Proximity ligation assays: a recent addition to the proteomics toolbox
- (2010) Irene Weibrecht et al. Expert Review of Proteomics
- Expansion of Hepatic Tumor Progenitor Cells in Pten-Null Mice Requires Liver Injury and Is Reversed by Loss of AKT2
- (2010) Vivian A. Galicia et al. GASTROENTEROLOGY
- Fyn is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration
- (2010) Vipin Yadav et al. MOLECULAR CARCINOGENESIS
- Architecture of Eph receptor clusters
- (2010) J. P. Himanen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Restriction of Receptor Movement Alters Cellular Response: Physical Force Sensing by EphA2
- (2010) K. Salaita et al. SCIENCE
- Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors
- (2009) Yongmun Choi et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- EphA2 Mediates Ligand-Dependent Inhibition and Ligand-Independent Promotion of Cell Migration and Invasion via a Reciprocal Regulatory Loop with Akt
- (2009) Hui Miao et al. CANCER CELL
- Oct4 and LIF/Stat3 Additively Induce Krüppel Factors to Sustain Embryonic Stem Cell Self-Renewal
- (2009) John Hall et al. Cell Stem Cell
- Overexpression of EphA2, MMP-9, and MVD-CD34 in hepatocellular carcinoma: Implications for tumor progression and prognosis
- (2009) Pu Yang et al. HEPATOLOGY RESEARCH
- STAT3 Is Required for Proliferation and Maintenance of Multipotency in Glioblastoma Stem Cells
- (2009) Maureen M. Sherry et al. STEM CELLS
- Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer
- (2008) Q Chang et al. BRITISH JOURNAL OF CANCER
- Role of Cyclin D1 as a Mediator of c-Met- and -Catenin-Induced Hepatocarcinogenesis
- (2008) M. A. Patil et al. CANCER RESEARCH
- Clathrin-Mediated Internalization Is Essential for Sustained EGFR Signaling but Dispensable for Degradation
- (2008) Sara Sigismund et al. DEVELOPMENTAL CELL
- Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
- (2008) Augusto Villanueva et al. GASTROENTEROLOGY
- Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene
- (2008) Benjamin Cieply et al. HEPATOLOGY
- Identification and Functional Analysis of Phosphorylated Tyrosine Residues within EphA2 Receptor Tyrosine Kinase
- (2008) Wei Bin Fang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation
- (2008) Stéphanie Kermorgant et al. JOURNAL OF CELL BIOLOGY
- The EphA2 Receptor and EphrinA1 Ligand in Solid Tumors: Function and Therapeutic Targeting
- (2008) J. Wykosky et al. MOLECULAR CANCER RESEARCH
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now